Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Drug-loaded nanobots for transmucosal delivery to mucinous tumours

Project description

Nanobot-enhanced drug delivery for mucus-secreting tumours

Mucus-secreting tumours such as pseudomyxoma peritonei (PMP) are characterised by the production of mucus, which can be found in various organs and normally acts as a defensive barrier for underlying cells. These tumours often present diagnostic and therapeutic challenges due to their tendency to produce thick, sticky mucus that can complicate treatment and contribute to aggressive disease progression. The ERC-funded MucOncoBots project aims to improve drug delivery for PMP by developing nanobots that can penetrate the mucus barrier and improve treatment efficacy. The study utilises patient-derived organoids and xenografts and is in the process of comparing this approach with standard care, aiming to translate findings into clinical practice.

Objective

Mucus is a defensive barrier that protects the underlying cells from pathogens and toxic compounds, although it also hinders the delivery of drugs whenever they are administered locally. There are different types of mucus-secreting tumours, such as pseudomyxoma peritonei (PMP), that could benefit from more efficient transmucosal delivery of anti-cancer drugs. PMP is a rare disease and the most mucinous tumour type, thus it will be used as a proof of concept for this project. In fact, it is characterised by the production of abundant mucus in the peritoneal cavity and is treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, usually Mitomycin C. This approach has extended patient survival, but there is a significant proportion of recurrence, most probably due to the shielding effect of mucus. Therefore, there is an urgent need to offer new therapeutic strategies to PMP patients. Recently, Dr. Palmer’s lab has established a collection of PMP patient-derived organoids and xenografts and has shown that some PMP patients present oncogenic BRAFV600E mutations, introducing a new druggable targeted mutation. In this proposal, Dr. Sánchez’s lab (IBEC), in collaboration with Dr. Palmer’s research group (VHIO), aims to use nanobots able to overcome the mucus barrier that will be loaded with Mitomycin C or Encorafenib (BRAF inhibitor) to treat PMP. A comparative study will be performed to assess the treatment’s efficacy compared to the standard of care, and medical advice will be received from Dr. Élez (VHUH) to ensure the translation of the results to the clinic. We believe that using this all-in-one system will certainly enhance the delivery and efficacy of the active therapeutic compound, thus potentially improving current treatments.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Net EU contribution
€ 127 500,00
Address
CARRER BALDIRI REIXAC PLANTA 2A 10-12
08028 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (2)